Plasma Derived Therapy Market Size – Analysis Report, 2032

Plasma Derived Therapy Market - By Product (Immunoglobulins, Coagulation Factors, Albumin), Application (Hemophilia, Primary Immunodeficiency Diseases, Idiopathic/Immune Thrombocytopenic Purpura (ITP)), Global Forecast, 2023-2032 

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Forecast calculation

1.1&nbsp;&nbsp;&nbsp; Covid-19 impact analysis at global level

1.2&nbsp;&nbsp;&nbsp; Data validation

1.3&nbsp;&nbsp;&nbsp; Data sources

1.3.1&nbsp;&nbsp;&nbsp; Primary

1.3.2&nbsp;&nbsp;&nbsp; Secondary

1.3.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.3.2.2&nbsp;&nbsp;&nbsp;Public sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Plasma derived therapy industry 360&deg; synopsis, 2018 &ndash; 2032

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Product trends

2.1.3&nbsp;&nbsp;&nbsp; Application trends

2.1.4&nbsp;&nbsp;&nbsp; Regional trends

Chapter 3&nbsp;&nbsp;&nbsp;Plasma Derived Therapy Industry&nbsp;Insights

3.1&nbsp;&nbsp;&nbsp; Industry segmentation

3.2&nbsp;&nbsp;&nbsp; Industry landscape, 2018 &ndash; 2032 (USD Million)

3.3&nbsp;&nbsp;&nbsp; Industry impact forces

3.3.1&nbsp;&nbsp;&nbsp; Growth drivers

3.3.1.1&nbsp;&nbsp;&nbsp;Increasing prevalence of rare diseases

3.3.1.2&nbsp;&nbsp;&nbsp;Growing demand for advanced therapeutic for treatment of genetic disorders

3.3.1.3&nbsp;&nbsp;&nbsp;Increase in number of plasma collection centers across the globe

3.3.1.4&nbsp;&nbsp;&nbsp;Rising adoption of immunoglobulins across the nation

3.3.2&nbsp;&nbsp;&nbsp; Industry pitfalls and challenges

3.3.2.1&nbsp;&nbsp;&nbsp;Stringent regulatory policies

3.4&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4.1&nbsp;&nbsp;&nbsp; By product

3.4.2&nbsp;&nbsp;&nbsp; By application

3.5&nbsp;&nbsp;&nbsp; COVID-19 impact analysis

3.6&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6.1&nbsp;&nbsp;&nbsp; U.S.

3.6.2&nbsp;&nbsp;&nbsp; Europe

3.7&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.8&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Competitive analysis of major market players, 2022

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix, 2022

4.5&nbsp;&nbsp;&nbsp; Strategic dashboard, 2022

Chapter 5&nbsp;&nbsp;&nbsp;Plasma Derived Therapy Market Estimates and Forecast, By Product, 2018-2032 (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by product

5.2&nbsp;&nbsp;&nbsp; Immunoglobulins

5.3&nbsp;&nbsp;&nbsp; Coagulation factors

5.4&nbsp;&nbsp;&nbsp; Albumin

5.5&nbsp;&nbsp;&nbsp; Other products

Chapter 6&nbsp;&nbsp;&nbsp;Plasma Derived Therapy Market Estimates and Forecast, By Application, 2018-2032 (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by application

6.2&nbsp;&nbsp;&nbsp; Hemophilia

6.3&nbsp;&nbsp;&nbsp; Primary immunodeficiency diseases

6.4&nbsp;&nbsp;&nbsp; Idiopathic/Immune thrombocytopenic purpura (ITP)

6.5&nbsp;&nbsp;&nbsp; Other applications

Chapter 7&nbsp;&nbsp;&nbsp;Plasma Derived Therapy Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by region

7.2&nbsp;&nbsp;&nbsp; North America

7.2.1&nbsp;&nbsp;&nbsp; U.S.

7.2.2&nbsp;&nbsp;&nbsp; Canada

7.3&nbsp;&nbsp;&nbsp; Europe

7.3.1&nbsp;&nbsp;&nbsp; Germany

7.3.2&nbsp;&nbsp;&nbsp; UK

7.3.3&nbsp;&nbsp;&nbsp; France

7.3.4&nbsp;&nbsp;&nbsp; Spain

7.3.5&nbsp;&nbsp;&nbsp; Italy

7.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

7.4&nbsp;&nbsp;&nbsp; Asia Pacific

7.4.1&nbsp;&nbsp;&nbsp; China

7.4.2&nbsp;&nbsp;&nbsp; Japan

7.4.3&nbsp;&nbsp;&nbsp; India

7.4.4&nbsp;&nbsp;&nbsp; Australia

7.4.5&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

7.5&nbsp;&nbsp;&nbsp; Latin America

7.5.1&nbsp;&nbsp;&nbsp; Brazil

7.5.2&nbsp;&nbsp;&nbsp; Mexico

7.5.3&nbsp;&nbsp;&nbsp; Argentina

7.5.4&nbsp;&nbsp;&nbsp; Rest of Latin America

7.6&nbsp;&nbsp;&nbsp; Middle East &amp; Africa

7.6.1&nbsp;&nbsp;&nbsp; South Africa

7.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

7.6.3&nbsp;&nbsp;&nbsp; UAE

7.6.4&nbsp;&nbsp;&nbsp; Rest of Middle East &amp; Africa

Chapter 8&nbsp;&nbsp;&nbsp;Company Profiles

8.1&nbsp;&nbsp;&nbsp; CSL Behring

8.2&nbsp;&nbsp;&nbsp; Takeda Pharmaceutical Company Limited.

8.3&nbsp;&nbsp;&nbsp; Biotest AG

8.4&nbsp;&nbsp;&nbsp; Octapharma

8.5&nbsp;&nbsp;&nbsp; BPL

8.6&nbsp;&nbsp;&nbsp; ADMA Biologics

8.7&nbsp;&nbsp;&nbsp; Grifols, SA

8.8&nbsp;&nbsp;&nbsp; Kedrion

8.9&nbsp;&nbsp;&nbsp; Kamada Pharmaceuticals.

8.10&nbsp;&nbsp;&nbsp; SK Plasma

8.11&nbsp;&nbsp;&nbsp; Pfizer, Inc. 
&nbsp;

Plasma Derived Therapy Market

Get a free sample of this report